Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017686 | 0.65 | GSK3B (0.37) | GSK3BTNKS2GAAIDH1 | |
| SCHEMBL828557 | 0.64 | IDH1 (0.43) | IDH1 | |
| SCHEMBL11914645 | 0.64 | GSK3B (0.47) | GSK3BTNKS2GAAIDH1 | |
| SCHEMBL14254518 | 0.63 | BRD4 (0.40) | GAA | |
| SCHEMBL12510427 | 0.61 | GSK3B (0.56) | GSK3BTNKS2GAA | |
| SCHEMBL19411558 | 0.61 | GSK3B (0.48) | GSK3BTNKS2 | |
| SCHEMBL12370921 | 0.60 | GRIA2 (0.35) | TNKS2IDH1 | |
| SCHEMBL22049622 | 0.59 | PDE2A (0.44) | GSK3B | |
| SCHEMBL9197462 | 0.58 | GSK3B (0.47) | GSK3BTNKS2GAA | |
| SCHEMBL24635835 | 0.58 | HTR2A (0.36) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-7939677-B2 | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7875733-B2 | Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing | ISIS PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7759480-B2 | Chloral-free DCA in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7713944-B2 | Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080119645-A1 | Immobilization; solid phase synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | LSIS PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7348391-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-7276599-B2 | Oligonucleotide synthesis with alternative solvents | ISIS PHARMACEUTICALS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070123703-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7169916-B2 | Chloral-free DCA in oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | GSK3B 3898/4885TNKS2 998/4885GAA 2060/4885 |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | GSK3B 3231/4885TNKS2 1208/4885GAA 4678/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | GSK3B 3898/4885TNKS2 998/4885GAA 2060/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | GSK3B 3898/4885TNKS2 998/4885GAA 2060/4885 |
| US-20080119645-A1 | Immobilization; solid phase synthesis | RNGTT, NOP2, NSUN2 | GSK3B 4298/4885TNKS2 223/4885GAA 2001/4885 |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | SNRPE, NSUN3, NSUN2 | GSK3B 3780/4885TNKS2 1138/4885GAA 2918/4885 |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | GSK3B 3898/4885TNKS2 998/4885GAA 2060/4885 |
| US-20070123703-A1 | CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS | DCLRE1B, DCTD, DDT | GSK3B 4504/4885TNKS2 3443/4885GAA 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.